Adocia Announces Financial Calendar for 2026

Financial Communication Schedule

According to the company, the first financial announcement will take place on February 24, 2026, with the publication of the revenue for the fourth quarter of 2025. The annual results for the fiscal year 2025 will be revealed on April 21, 2026. The revenue for the first quarter of 2026 is expected on May 12, followed by the general meeting of shareholders scheduled for June 3, 2026. The latter half of the year will see the revenue for the second quarter published on July 23, 2026, followed by the publication of the semi-annual results on June 30, 2026, on September 24, 2026. The calendar will conclude with the announcement of the third quarter revenue, scheduled for October 29, 2026.

Access to Corporate Information

The company indicates that investors can visit its website to regularly follow the financial and operational news. According to the press release, all corporate information, including financial statements, investor presentations, and company statutes, is available in the regulated information section of the group's website. This availability is part of the communication obligations of companies listed on the Euronext Paris market.

Company Profile

Adocia positions itself as a biotechnology company specializing in the discovery and development of therapeutic solutions for metabolic diseases, particularly diabetes and obesity. The group has a portfolio of drug candidates based on four proprietary technological platforms: BioChaperone for the stabilization of peptide formulations, AdOral for oral peptide delivery, AdoShell, a biomaterial for pancreatic cell transplantation, and AdoXLong for the extended action of peptides. The company, which holds more than 25 patent families and employs about 80 staff at its Lyon facilities, is listed on Euronext Paris.